Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: A preliminary analysis

Modern Rheumatology

Volumn 16, Issue 2, 2006, Pages 77-84

  Tanno, Makoto ^a   Nakamura, Ichiro ^a   Ito, Katsumi ^a   Tanaka, Hidekazu ^b   Ohta, Hisahiko ^c   Kobayashi, Makoto ^d   Tachihara, Akitoshi ^c   Nagashima, Masakazu ^c   Yoshino, Shinichi ^c   Nakajima, Atsuo ^c  

^a Yugawara Kosei Nenkin Hospital   (Japan)

^b Tokyo Metropolitan Rehabilitation Hospital   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d Crecon Research and Consulting Inc   (Japan)

Author keywords

Anti tumor necrosis factor (TNF) ; Cost effectiveness analysis; Disease modifying antirheumatic drug (DMARD); Etanercept; Japan; Rheumatoid arthritis (RA)

Indexed keywords

BUCILLAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LANSOPRAZOLE; METHOTREXATE; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HEALTH STATUS; IMMUNOGLOBULIN G; JAPAN; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 33645990293     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-006-0461-y     Document Type: Article

References (38)

1. K Shichikawa K Inoue S Hirota A Maeda H Ota M Kimura et al. 1999 Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996 Ann Rheum Dis 58 12 751-6 1:STN:280:DC%2BD3c%2Fks12msQ%3D%3D 10577961
2. AJ Silman JE Pearson 2002 Epidemiology and genetics of rheumatoid arthritis Arthritis Res 4 Suppl 3 S265-72 10.1186/ar578 12110146
3. Y Matsuda G Singh H Yamanaka E Tanaka W Urano Taniguchi et al. 2003 Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3763 patients with rheumatoid arthritis Arthritis Rheum 49 6 784-8 10.1002/art.11465 14673964
4. Mithal A, Yamanaka H, Tanaka EI, Nakajima A, Kamatani N. Medical costs for care of rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference; 2003 September 1-3; Kobe, Japan
5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines 2002 Guidelines for the management of rheumatoid arthritis: 2002 Update Arthritis Rheum 46 2 328-46 10.1002/art.10148
6. Yamanaka H, Mithal A, Tanaka EI, Nakajima A, Kamatani N. Medical costs are significantly associated with disability levels in rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference, September 1-3; Kobe, Japan; 2003
7. S Schwartzman R Fleischmann GJ Morgan Jr 2004 Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 6 Suppl 2 S3-11 1:CAS:528:DC%2BD2cXhtValtr7M 15228615
8. JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff EC Keystone et al. 2000 A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 22 1586-93 10.1056/ NEJM200011303432201 1:CAS:528:DC%2BD3cXovVeltLg%3D 11096165
9. MC Genovese JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff et al. 2002 Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes Arthritis Rheum 46 6 1443-50 10.1002/art.10308 1:CAS:528:DC%2BD38Xltlantbk%3D 12115173
10. LW Moreland MH Schiff SW Baumgartner EA Tindall RM Fleischmann KJ Bulpitt et al. 1999 Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 6 478-86 1:CAS:528:DyaK1MXitFChs7Y%3D 10075615
11. ME Weinblatt JM Kremer AD Bankhurst KJ Bulpitt RM Fleischmann RI Fox et al. 1999 A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 4 253-9 10.1056/ NEJM199901283400401 1:CAS:528:DyaK1MXht1Wqsbk%3D 9920948
12. LW Moreland SB Cohen SW Baumgartner EA Tindall K Bulpitt R Martin et al. 2001 Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis J Rheumatol 28 6 1238-44 1:CAS:528:DC%2BD3MXkvVOhu7g%3D 11409115
13. S Nishimura GW Torrance N Ikegami S Fukuhara M Drummond F Schubert 2002 Information barriers to the implementation of economic evaluations in Japan Pharmacoeconomics 20 Suppl 2 9-15 12238944
14. J Doherty K Sato 2003 Practical aspects of designing and conducting pharmacoeconomic studies in Japan Pharmacoeconomics 21 13 913-25 10.2165/ 00019053-200321130-00001 12959624
15. H Matsuno E Sugiyama A Muraguchi T Nezuka T Kubo K Matsuura et al. 1998 Pharmacological effects of SA96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of SA-96 metabolites plays a critical role in the pharmacological action of the drug Int J Immunopharmacol 20 6 295-304 10.1016/S0192-0561(98)00012-5 1:CAS:528:DyaK1cXlslGgtLY%3D 9754677
16. T Azuma 1992 Epidemiology, prognosis and causes of death in rheumatoid arthritis Nippon Rinsho 50 3 637-43 1:STN:280:By2B28bkvVA%3D 1588761
17. S Kawai T Kato T Matsuda 2002 Quality of life measures as clinical assessment of improvement in rheumatoid arthritis Recent Adv Clin Pharmacol 23 47-51
18. Y Ichikawa T Shinozawa T Yoshida H Kameda Y Suzuki S Kawai et al. 1995 [Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis] Ryumachi (Rheumatism) 35 4 663-70 1:STN:280:BymD3M7gsVA%3D
19. Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Correlation between the health assessment questionnaire (HAQ) and utility value in rheumatoid arthritis patients. In: ISPOR first Asia-Pacific conference, September 1-3; Kobe, Japan; 2003
20. A Brennan N Bansback A Reynolds P Conway 2004 Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology (Oxford) 43 1 62-72 10.1093/rheumatology/keg451 1:STN:280:DC%2BD3sngtVSltQ%3D%3D
21. V Strand S Cohen M Schiff A Weaver R Fleischmann G Cannon et al. 1999 Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group Arch Intern Med 159 21 2542-50 10.1001/archinte.159.21.2542 1:CAS:528:DyaK1MXotVSnurg%3D 10573044
22. JS Smolen JR Kalden DL Scott B Rozman TK Kvien A Larsen et al. 1999 Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group Lancet 353 9149 259-66 10.1016/S0140-6736(98)09403-3 1:CAS:528:DyaK1MXhsF2lsr4%3D 9929017
23. AK Mohan TR Cote JA Block AM Manadan JN Siegel MM Braun 2004 Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor Clin Infect Dis 39 3 295-9 10.1086/421494 1:CAS:528:DC%2BD2cXnsFSmt7o%3D 15306993
24. S Kashiwazaki Y Ichikawa S Sugawara I Nagaya S Kawai M Hakota et al. 1996 Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis Jpn J Inflamm 16 6 437-57
25. N Nishioka M Nobunaga A Sakuma 1991 [A double blind comparative study of 1g/day, 2g/day salazosulfapyridine and placebo in rheumatoid arthritis] Ryumachi (Rheumatism) 31 3 327-45 1:STN:280:By2D2Mrgtl0%3D
26. V Saravanan CA Kelly 2004 Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis Rheumatology (Oxford) 43 2 143-7 1:STN:280:DC%2BD2c%2FktVWgsg%3D%3D
27. Wages and Labour Welfare Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Report of Basic Survey on Wage Structure, 2001. Japan: 2002
28. Population Census Division, Statistical Survey Department, Statistics Bureau, Ministry of Public Management, Home Affairs, Post and Telecommunications 2002 Annual Report on the Labour Force Survey Japan Statistical Association Tokyo
29. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare. Abridged Life Tables for Japan 2003. On Ministry website (updated 2004 Aug 18; cited 2004 Nov 23). Available from: Http://www.mhlw.go.jp/english/database/db-hw/lifetb03/
30. F Wolfe SM Kleinheksel MA Cathey DJ Hawley PW Spitz JF Fries 1988 The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis J Rheumatol 15 10 1480-8 1:STN:280:BiaD1c7isFc%3D 3204597
31. National Institute for Clinical Excellence 2001 Guidance for Manufacturers and Sponsors National Institute for Clinical Excellence London, England
32. S Merkesdal J Ruof T Mittendorf H Zeidler 2004 Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis Expert Opin Pharmacother 5 9 1881-6 10.1517/14656566.5.9.1881 1:CAS:528:DC%2BD2cXmvFSmsLs%3D 15330726
33. DK Owens 1998 Interpretation of cost-effectiveness analyses J Gen Intern Med 13 10 716-7 1:STN:280:DyaK1M%2FhtlWltA%3D%3D 9798822
34. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. On National Institute for Clinical Excellence website (updated 2004 Apr 30; cited 2004 May 5). Available from: Http:// www.nice.org.uk/pdf/TAP_Methods.pdf
35. G Kobelt K Eberhardt P Geborek 2004 TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden Ann Rheum Dis 63 1 4-10 10.1136/ ard.2003.010629 1:CAS:528:DC%2BD2cXotlOiuw%3D%3D 14672883
36. Ota H, Tanno M, Tanaka H, Kobayashi M, Yoshino S. Patient reported outcomes for rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference, September 1-3; Kobe, Japan; 2003
37. JM Kremer ME Weinblatt AD Bankhurst KJ Bulpitt RM Fleischmann CG Jackson et al. 2003 Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations Arthritis Rheum 48 6 1493-9 10.1002/art.11142 1:CAS:528:DC%2BD3sXltlSgtbY%3D 12794815
38. L Klareskog D van der Heijde JP De Jager A Gough J Kalden M Malaise et al. 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 363 9410 675-81 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D 15001324